Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Recurrent Laryngeal Nerve Monitoring During Pediatric Aerodigestive Tract and Cardiac Surgery

19 mai 2026 mis à jour par: Andre Isaac, University of Alberta

Recurrent Laryngeal Nerve Monitoring During Pediatric Aerodigestive Tract and Cardiac Surgery: A Randomized Double-blinded Controlled Trial

This research studies whether a device used during surgery can help doctors better protect the nerve that moves a child's vocal cords. Damage to this nerve can affect speaking, swallowing, and sometimes breathing. Children having certain throat, chest, or heart surgeries may be asked to take part. During surgery, some children will have standard care and others will have standard care plus the nerve-monitoring device. After surgery, the team will check vocal cord movement and ask about voice and swallowing. The purpose is to see whether the device can lower the chance of nerve injury and improve care for children in the future.

Aperçu de l'étude

Description détaillée

Purpose The purpose of this study is to compare the rate of recurrent laryngeal nerve (RLN) injury in pediatric patients undergoing aerodigestive and cardiac surgeries with intraoperative laryngeal nerve monitoring (IOLNM) versus standard surgery without IOLNM. The study also aims to evaluate whether continuous electromyography monitoring reduces clinically detectable postoperative nerve dysfunction in children undergoing RLN-risk surgery.

Hypothesis The investigators hypothesize that patients who undergo surgery with IOLNM will have a lower rate of RLN injury, less severe nerve injury when injury occurs, and a shorter duration of neuropraxia/vocal cord paresis compared with patients who undergo standard surgery without monitoring.

Justification Vocal cord paralysis is a recognized complication of pediatric thyroid, airway, esophageal, and cardiac surgery because the RLN is vulnerable along its course through the neck and chest. RLN injury can lead to dysphonia, dysphagia, aspiration, and respiratory insufficiency, making prevention clinically important. Existing evidence suggests IOLNM may reduce RLN injury, especially in pediatric surgery where some procedures have reported injury rates as high as 40%; however, the current literature is limited by a lack of prospective randomized studies and lack of direct prospective comparison against standard surgical care. The recent availability of pediatric-compatible monitoring electrodes also makes this question feasible to study in infants and young children.

Research Method/Procedures This is a single-centre, randomized, double-blinded, controlled clinical trial conducted at Stollery Children's Hospital. Eligible participants are patients under 18 years of age undergoing RLN-risk surgery involving the trachea, esophagus, thyroid, mediastinum, ductus arteriosus, or aortic arch, with specified inclusion and exclusion criteria. Participants, study investigators, clinicians performing follow-up flexible laryngoscopy, and video raters are blinded to allocation; surgeons and personnel directly involved in intraoperative care cannot be blinded.

For participants randomized to the intervention arm, IOLNM is used during a single surgery. Surgery otherwise proceeds according to standard of care. Within four weeks of their surgery, participants are seen in follow-up by Dr. Isaac or another pediatric otolaryngologist. At that visit, they complete the PedsQL, PVRQOL, Pediatric VHI, and dysphagia questionnaires, and undergo video-recorded flexible fiberoptic laryngoscopy. The recorded laryngoscopy is anonymized and reviewed by a blinded independent expert. For patients with RLN injury, further clinical follow-up and repeat laryngoscopy every three months for at least one year or until recovery occur as part of standard care.

Safety monitoring is performed during surgery, the postoperative hospital stay, and follow-up visits. Adverse events related to IOLNM include, but are not limited to, laryngeal trauma, airway bleeding, or inflammation, and are reported to the study coordinator, principal investigator, and local HREB in accordance with institutional and Health Canada standards.

Type d'étude

Interventionnel

Inscription (Estimé)

90

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Alberta
      • Edmonton, Alberta, Canada, T6G2B7

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • under 18 years of age
  • treated at the Stollery Children's Hospital
  • will undergo specified aerodigestive or cardiac surgeries that put the recurrent laryngeal nerve at risk

Exclusion Criteria:

  • patients treated at another center
  • over 18 years of age at the time of surgery
  • severe neurological or genetic comorbidities that affect nerve function

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: La prévention
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Control Arm
Participants in this arm will receive standard care during surgery, without the use of intra-operative laryngeal nerve monitoring.
Expérimental: Intervention Arm
Participants enrolled in this arm will receive intra-operative recurrent laryngeal nerve monitoring during their surgery to determine if this intervention reduces the risk of developing recurrent laryngeal nerve injury.
This nerve monitor will notify surgeons if the recurrent laryngeal nerve is at risk for damage during surgery, by signalling if the nerve is being stretched or manipulated throughout the procedure.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Vocal fold mobility
Délai: Flexibly laryngoscopy will be performed within four weeks of the aerodigestive or cardiac surgery.
Vocal fold mobility will be assessed by flexible laryngoscopy on patients post operatively to determine if there has been RLN injury resulting in vocal cord immobility.
Flexibly laryngoscopy will be performed within four weeks of the aerodigestive or cardiac surgery.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Impact on voice in UVFI patients
Délai: The questionnaire will be given within four weeks of the UVFI diagnosis.
Voice-related quality of life questionnaire
The questionnaire will be given within four weeks of the UVFI diagnosis.
Severity of dysphonia in UVFI patients
Délai: Voice assessment will be completed within four weeks of UVFI diagnosis
Dysphonia measured by acoustic analysis and GRBAS assessment
Voice assessment will be completed within four weeks of UVFI diagnosis
Swallowing outcomes in UVFI patients
Délai: Swallowing assessments will be completed within four weeks of UVFI diagnosis and as recommended by SLP/ENT
Dysphagia will be measured by FEES and/or VFSS assessments
Swallowing assessments will be completed within four weeks of UVFI diagnosis and as recommended by SLP/ENT
Swallowing symptom burden in UVFI patients
Délai: Questionnaires will be given within four weeks of UVFI diagnosis
Impact on quality of life from dysphagia will be measured using validated questionnaires
Questionnaires will be given within four weeks of UVFI diagnosis
Rate of spontaneous resolution of UVFI
Délai: These outcomes will be measured by flexible laryngoscopy at 3 month and 6 month intervals after the time of UVFI diagnosis
Rate of vocal fold motion recovery, and time to recovery, assessed by flexibly laryngoscopy
These outcomes will be measured by flexible laryngoscopy at 3 month and 6 month intervals after the time of UVFI diagnosis

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 septembre 2026

Achèvement primaire (Estimé)

30 juin 2028

Achèvement de l'étude (Estimé)

30 juin 2028

Dates d'inscription aux études

Première soumission

12 mai 2026

Première soumission répondant aux critères de contrôle qualité

19 mai 2026

Première publication (Réel)

22 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

22 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

19 mai 2026

Dernière vérification

1 mai 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Oui

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner